SPC Logo

Locoid Scalp Lotion

Last Updated on eMC 03-Feb-2015 View changes  | Astellas Pharma Ltd Contact details

1. Name of the medicinal product


2. Qualitative and quantitative composition

Contains 0.1% w/v hydrocortisone butyrate.

For excipients, see 6.1

3. Pharmaceutical form

Cutaneous solution.

Clear, colourless solution.

4. Clinical particulars
4.1 Therapeutic indications

The product is recommended for clinical use in the treatment of scalp conditions responsive to topical corticosteroids e.g. eczema, dermatitis and psoriasis.

Topical corticosteroids are not generally indicated in psoriasis but may be acceptable in psoriasis excluding widespread plaque psoriasis provided warnings are given; see section 4.4 Special warnings and special precautions for use.

4.2 Posology and method of administration

For topical application to the scalp.

Dosage: To be applied evenly and sparingly no more than twice daily

Adults and the Elderly: The same dose is used for adults and the elderly, as clinical evidence would indicate that no special dosage regimen is necessary in the elderly.

Children: Long term treatment should be avoided where possible.

Infants: Therapy should be limited if possible to a maximum of seven days.

4.3 Contraindications

Hypersensitivity to hydrocortisone or to any of the ingredients of the lotion.

This preparation is contraindicated in the presence of untreated viral or fungal infections, tubercular or syphilitic lesions, peri-oral dermatitis, acne vulgaris and rosacea and in bacterial infections unless used in connection with appropriate chemotherapy.

4.4 Special warnings and precautions for use

Although generally regarded as safe, even for long-term administration in adults, there is a potential for adverse effects if over used in infancy. Extreme caution is required in dermatoses of infancy. In such patients courses of treatment should not normally exceed 7 days.

As with all corticosteroids, application to the face, flexures and other areas of thin skin may cause skin atrophy and increased absorption and should be avoided.

Topical corticosteroids may be hazardous in psoriasis for a number of reasons including rebound relapses following development of tolerance, risk of generalised pustular psoriasis and local and systemic toxicity due to impaired barrier function of the skin. Steroids may have a place in psoriasis of the scalp and chronic plaque psoriasis of the hands and feet. Careful patient supervision is important.

Keep away from eyes.

4.5 Interaction with other medicinal products and other forms of interaction

None known.

4.6 Pregnancy and lactation

There is inadequate evidence of safety in human pregnancy. Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate and intra-uterine growth retardation. There may therefore be a very small risk of such effects in the human foetus.

Theoretically, there is the possibility that if maternal systemic absorption occurred the infant's adrenal function could be affected.

The use of topical corticosteroids during lactation is unlikely to present a hazard to infants being breast-fed.

4.7 Effects on ability to drive and use machines

None known.

4.8 Undesirable effects

System Organ Class



Very rare


Not known

Immune system disorders



Endocrine disorders


Adrenal suppression


Skin and subcutaneous tissue disorders

Skin atrophy, often irreversible, with thinning of the epidermis


Skin striae

Pustular acne

Perioral dermatitis

Rebound effect

Skin depigmentation

Dermatitis and eczema, including contact dermatitis


Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9 Overdose

Excessive use under occlusive dressings may produce adrenal suppression. No special procedures or antidote. Treat any adverse effects symptomatically.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Hydrocortisone butyrate is a potent topical corticosteroid.

5.2 Pharmacokinetic properties

The topical activity has been demonstrated in vivo using the McKenzie-Stoughton test.

5.3 Preclinical safety data

No preclinical safety data have been generated.

6. Pharmaceutical particulars
6.1 List of excipients

Isopropyl alcohol, glycerol (85%), Povidone K90, anhydrous citric acid, anhydrous sodium citrate, purified water.

6.2 Incompatibilities

None stated.

6.3 Shelf life

2 years

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and contents of container

Plastic, dropper-necked screw cap vial.

Pack sizes: 30 ml and 100 ml.

6.6 Special precautions for disposal and other handling

No special requirements.

7. Marketing authorisation holder

Astellas Pharma Ltd.

2000 Hillswood Drive



KT16 0RS

United Kingdom

8. Marketing authorisation number(s)

PL 00166/0060R

9. Date of first authorisation/renewal of the authorisation

First authorised 28 September 1973; renewed 19 December 2003.

10. Date of revision of the text

28 January 2015

11. Legal category


Company contact details

Astellas Pharma Ltd

Company image

2000 Hillswood Drive, Chertsey, Surrey, KT16 0RS, UK


+44 (0) 203 379 8820

Medical Information e-mail

+44 (0) 203 379 8700

Medical Information Direct Line

0800 783 5018

Stock Availability

+44 (0) 203 379 8721

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

hydrocortisone butyrate

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue